Roche Spin-Off Basilea Will Take Over Dermatologic, Anti-Infective R&D
Executive Summary
Roche is outsourcing its dermatological and infectious diseases research programs through the R&D spin-off Basilea Pharmaceutica.
You may also be interested in...
Accutane Once-Daily Version Should Have Three-Year Phase-In - FDA Cmte.
Roche should take three years to replace the current formulation of Accutane (isotretinoin) with a once-daily version, FDA Dermatologic & Ophthalmic Drugs Advisory Committee voting consultant Lloyd King, MD/PhD, said during the panel's Sept. 19 meeting.
Roche Kytril Acquisition From SmithKline Strengthens Hospital Focus In U.S.
Roche's acquisition of the anti-emetic Kytril from SmithKline Beecham will build on Roche's strength in the U.S. hospital market.
Roche Likes Its Critical Mass But Could Amass More; $2 Bil. R&D Will Do
Roche's restructuring and internal growth obviates the need for a merger, even with the recent loss of several late-phase clinical projects, CEO Franz Humer told the Roche 1999 annual earnings conference March 30 in Basel.